Evidence map›Paper›PMID 21370032›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2011

Signaling events initiated by kappa opioid receptor activation: quantification and immunocolocalization using phospho-selective KOR, p38 MAPK, and K(IR) 3.1 antibodies.

Julia C Lemos, Clarisse A Roth, Charles Chavkin

Open access · greenAbstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. The Impact ofInternational journal of molecular sciences · 2023
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Locus coeruleus kappa-opioid receptors modulate reinstatement of cocaine place preference through a noradrenergic mechanism.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2013
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Julia C LemosDepartment of Pharmacology and Program for Neurobiology and Behavior, University of Washington, Seattle, WA, USA. jlemos27@u.washington.edu
Clarisse A Roth
Charles Chavkin
University of Washington · US

Funding

p38 MAPK Mechanisms of Kappa Opioid-Induced BehaviorsR01DA030074 · NIDA · UNIVERSITY OF WASHINGTON · PI CHAVKIN, CHARLES · 2011 to 2020
$3.2M
Regulation of Opioid Signaling by Tyr-PhosphorylationR37DA011672 · NIDA · UNIVERSITY OF WASHINGTON · PI CHAVKIN, CHARLES · 2004 to 2013
$2.5M
Opioid mediation of stress-potentiated cocaine responseR01DA016898 · NIDA · UNIVERSITY OF WASHINGTON · PI CHAVKIN, CHARLES · 2003 to 2007
$1.3M
Dynorphins and Kappa Opioid Receptors in the Stress ResponseK05DA020570 · NIDA · UNIVERSITY OF WASHINGTON · PI CHAVKIN, CHARLES · 2006 to 2015
$1.2M
NIDA NIH HHS K05 DA020570NIDA NIH HHS R01 DA016898NIDA NIH HHS R01 DA030074NIDA NIH HHS R37 DA011672
6 · The paper itself

Abstract

Psychiatric disorders including anxiety, depression, and addiction are both precipitated and exacerbated by severe or chronic stress exposure. While acutely, stress responses are adaptive, repeated exposure to stress can dysregulate the brain in such a way as to predispose the organism to both physiological and mental illness. Understanding the neuronal chemicals, cell types, and circuits involved in both normal and pathological stress responses are essential in developing new therapeutics for psychiatric diseases. Varying degrees of stressor exposure cause the release of a constellation of chemicals, including neuropeptides such as dynorphin. Neuropeptidergic release can be very difficult to directly measure with adequate spatial and temporal resolution. Moreover, the downstream consequences following release and receptor binding are numerous and also difficult to measure with cellular resolution. Following repeated stressor exposure, dynorphin is released, binds to the kappa opioid receptor (KOR), and causes activation of KOR. Agonist-activated KOR becomes a substrate for G protein receptor kinase (GRK), which phosphorylates the Ser369 residue at the C-terminal tail of the receptor in the first step in the β-Arrestin-dependent desensitization cascade. Through the use of phospho--selective antibodies developed and validated in the laboratory, we have the tools, to assess with fine cellular resolution, the strength of behavioral stimulus required for release, time course of the release, and regional location of release. We have gone on to show that following KOR activation, both ERK 1/2 and p38 MAP kinase phosphorylation are increased through use of commercially available phospho-selective antibodies. Finally, we have identified that one effector of KOR/p38MAP kinase is K(IR) 3.1 and have developed a phospho-selective antibody against the Y12 motif of this channel. Much like KOR and p38 MAP kinase, phosphorylation of this potassium channel increases following repeated stress. The following chapter discusses immunohistochemical and quantification methods used for phospho-selective antibodies used in various brain regions following behavioral manipulations.

Indexed as

Signal TransductionAnimalsAntibodies, Phospho-SpecificBrainCell LineChromatography, AffinityHumansImmunohistochemistryMiceMicroscopyMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3p38 Mitogen-Activated Protein KinasesPotassium Channels, Inwardly RectifyingRatsReceptors, Opioid, kappaAntibodies, Phospho-SpecificMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3p38 Mitogen-Activated Protein KinasesPotassium Channels, Inwardly RectifyingReceptors, Opioid, kappa

Identifiers

PMID21370032
PMCPMC3727639
OpenAlexW3390919

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.